Nano-silver clotrimazole formulations for enhanced treatment of vaginal yeast infections
A novel nano-silver clotrimazole formulation is being developed to improve the treatment of recurrent vaginal yeast infections by disrupting biofilms, enhancing drug efficacy, and preventing resistance. This non-prescription solution aims for effective, long-lasting results.
Overview
This innovative formulation combines the antifungal properties of clotrimazole with the potent antimicrobial capabilities of nano-silver to address recurrent vaginal yeast infections (VYI). By incorporating nano-silver, the formulation enhances the penetration and effectiveness of clotrimazole, targeting Candida overgrowth more efficiently. This solution aims to provide a non-prescription topical treatment that acts directly in the intimate area, offering a promising method to reduce recurrence rates and mitigate drug resistance.
Technical specifications
Key features:
- Nano-silver incorporation: Utilizes the antimicrobial properties of nano-silver to disrupt biofilms, increasing clotrimazole's effectiveness.
- Enhanced antifungal activity: Specifically targets and reduces Candida species, which are common causes of VYI.
- Non-prescription formulation: Designed for easy application and direct action in the intimate area.
Development phases:
- Formulation Development: Synthesis and characterization of nano-silver particles, followed by their integration into clotrimazole formulations.
- In Vitro Studies: Evaluation of antifungal activity, biofilm disruption, and cytotoxicity.
- In Vivo Studies: Preclinical trials to assess efficacy and safety.
- Clinical Trials: Safety, tolerability, and efficacy assessments in humans.
- Regulatory Approval and Commercialization: Preparation for OTC approval and market readiness.
Technology readiness level
Currently at Technology Readiness Level 3, this formulation is in the early stages of development, focusing on synthesis and initial in vitro evaluations. Future steps include rigorous in vivo testing and clinical trials to ensure efficacy and safety before seeking regulatory approval and commercialization.
About National Yang-Ming University
National Yang‑Ming University was a national, medical‑ and life‑sciences–focused public research university in Taipei with a strong clinical orientation. The Shipai campus sat adjacent to Taipei Veterans General Hospital, which served as its principal teaching hospital and enabled rapid clinical collaboration and translation. The university also operated an affiliated university hospital in Yilan, supporting multi‑site clinical research and training. Its research was backed by competitive national funding in Taiwan, notably from the National Science and Technology Council. Following its merger with National Chiao Tung University on February 1, 2021, these programs and hospital partnerships now operate within National Yang Ming Chiao Tung University’s Yangming campus, supported by dedicated industry–academia and technology transfer offices.
Inquire about this partnering listing
Industry applications
delivered to your inbox.